Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...

Michael J. Fox established The Michael J. Fox Foundation for Parkinson's Research in 2000 after his diagnosis. The foundation has funded over $3 billion in research aimed at developing treatments and ...

Gain Therapeutics’ lead drug candidate rexaceract, formerly known as GT-02287, is in clinical development for the treatment ...

Tavapadon (Juvmo) is a new once-daily pill for Parkinson’s motor symptoms. Here’s how it works, who it may help and what to ...

As part of its unwavering commitment to accelerate Parkinson's research, The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announces All Grit. No Quit. — an ambitious multi-year $2.5 ...

University of Wisconsin researchers opened a new path to curing Parkinson’s disease through grafting brain cells into the brains of macaque monkeys. The research, conducted at the Wisconsin National ...

Since its inception in 2000, The Michael J. Fox Foundation has become the world’s largest nonprofit funder of Parkinson’s research, recently marking over $3 billion in total contributions toward ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

A Northwestern Medicine research lab has found a usually harmless virus in brain samples from Parkinson’s patients. The idea that Parkinson’s could be linked to a virus had been theorized for years, ...

A small study found disease-related odor compounds may show up in skin samples, including from the navel, but much larger trials are needed.

A toddler developed an infection and trapped air behind her throat three weeks after tonsil and adenoid surgery, a rare and delayed complication. Henderson Hospital Stops Delivering Babies September ...